Postthrombolysis Outcomes in Acute Ischemic Stroke Patients of Asian Race-Ethnicity

Abstract

Background

Race-ethnic differences may influence postthrombolysis outcomes in acute ischemic stroke patients. Guidelines for thrombolytic therapy to treat Asian stroke patients are based mostly on extrapolated western data.

Aims

We undertook to examine outcomes among Asians by comparing a propensity-matched cohort of thrombolyzed patients from a tertiary center in Singapore with nonthrombolyzed Asian comparators collated from Virtual International Stroke Trials Archives (control).

Methods

We identified propensity scores-matched patients between thrombolyzed and control Asian patients lodged in the Virtual International Stroke Trials Archives by employing propensity scores method. We compared matched patients for their distributions of three-month functional (modified Rankin scores) and neurological outcomes (National Institute of Health Stroke Scale) by employing Cochran–Mantel–Haenszel test and proportional odds logistic regression analysis. We report odds ratio and 95% confidence interval for improved outcomes on day 90.

Results

Virtual International Stroke Trials Archives and National University Hospital, Singapore, contributed 517 and 133 patients of Asian race-ethnicity (n = 650), respectively. After propensity matching, sample size reduced to 237 patients; 104 were from Virtual International Stroke Trials Archives. Age (59·7 vs. 61·5 years, P = 0·2) and mean baseline National Institute of Health Stroke Scale scores were similar (14) between thrombolyzed and control. The odds ratio for shift toward improved modified Rankin scores and National Institute of Health Stroke Scale distributions after tissue plasminogen activator therapy were 2·8 (95% confidence interval 1·8–4·5, P < 0·0001, n = 233; Cochran–Mantel–Haenszel P < 0·0001) and 2·8 (95% confidence interval 1·7–4·7, P = 0·0008, n = 201; Cochran–Mantel–Haenszel P = 0·0001).

Conclusions

Our data indicate that Asian patients derive benefit from thrombolytic therapy.

Keywords

Asian race-ethnicity guidelines outcomes propensity stroke thrombolysis tissue plasminogen activator

Get full access to this article

View all access options for this article.

References

European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457–507.

Adams

Jr Del Zoppo

Alberts

. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655–711.

Xian

Holloway

Noyes

Shah

Friedman

. Racial differences in mortality among patients with acute ischemic stroke: an observational study. Ann Intern Med 2011; 154:152–9.

Cruz-Flores

Rabinstein

Biller

. Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:2091–116.

Sharma

Tsivgoulis

Teoh

Ong

Chan

. Stroke risk factors and outcomes among various Asian ethnic groups in Singapore. J Stroke Cerebrovasc Dis 2012; 21:299–304.

Chao

Hsu

Chung

. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke 2010; 41:885–90.

Nakagawara

Minematsu

Okada

. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan Post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41:1984–9.

Yamaguchi

Mori

Minematsu

. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37:1810–5.

Mori

Minematsu

Nakagawara

Yamaguchi

Sasaki

Hirano

. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41:461–5.

10.

Ueshima

Matsuo

. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost 2002; 87:544–6.

11.

Sane

Stump

Topol

. Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Circulation 1991; 83:170–5.

12.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581–7.

13.

Summary information on a referral opinion following an arbitration pursuant to article 29 of directive 2001/83/EC for Actilyse (dated November 21, 2002; CPMP/3346/02-EN), 2002. Prepared by the Committee for Proprietary Medicinal Products (CPMP) for the European Agency for the Evaluation of Medicinal Products. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Actilyse_29/WC500010327.pdf Also available at Summary of Product characteristics for Alteplase http://www.medicines.org.uk/EMC/searchresults.aspx?term=actilyse&searchtype=QuickSearch

14.

Wahlgren

Ahmed

Davalos

. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275–82.

15.

Hacke

Kaste

Bluhmki

. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317–29.

16.

Ghandehari

. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat 2011; 2011:686797.

17.

Ali

Bath

Curram

. The Virtual International Stroke Trials Archive. Stroke 2007; 38:1905–10.

18.

Mishra

Diener

Lyden

Bluhmki

Lees

. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010; 41:2840–8.

19.

Sharma

Tsivgoulis

Tan

. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis 2010; 19:424–30.

20.

Mishra

Ahmed

Andersen

. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010; 341:c6046.

21.

Rosenbaum

Rubin

. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41–55.

22.

D'Agostino

Jr . Propensity scores in cardiovascular research. Circulation 2007; 115:2340–3.

23.

Rubin

. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757–63.

24.

Mantel

. Chi square tests with one degree of freedom: extension of Mantel-Haenszel procedure. J Am Stat Assoc 1963; 58:690–700.

25.

Marc

. Gameroff, Using the Proportional Odds Model for Health-Related Outcomes: Why, When, and How with Various SAS® Procedures. New York, New York State Psychiatric Institute, 2005. http://www2.sas.com/proceedings/sugi30/205-30.pdf (accessed 4 December 2012).

26.

Rubin

. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001;2:169–88. http://archlab.gmu.edu/people/jthompsz/rubin.pdf

27.

Ministry of health: population and vital statistics source. http://www.moh.gov.sg/mohcorp/statistics.aspx (accessed October 3, 2011).

28.

Savitz

Lew

Bluhmki

Hacke

Fisher

. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke 2007; 38:3205–12.

29.

Padma

Singh

Bhatia

. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India 2007; 55:46–9.

30.

Sharma

. Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective. Ann Indian Acad Neurol 2008; 11:221–4.

31.

Sharma

Venketasubramanian

. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke 2011; 6:523–30.

32.

Safe Implementation of Treatments in Stroke – South and South East Asia; https://sitsinternational.org/homefoldercontent/registry/sits_studies (accessed 4th December 2012).

33.

Deeks

Dinnes

D'Amico

. Evaluating non-randomised intervention studies Health Technol Assess 2003;7:iii–x, 1–173. http://www.hta.ac.uk/fullmono/mon727.pdf

34.

Lees

Bluhmki

Von Kummer

. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695–703.